Prostate cancer screening: What physicians and patients need to know

New video series features urology expert on benefits, medical evidence and questions for screenings

Alan J. Wein, MD, FACS, PhD (hon)Prostate cancer awareness and diagnoses are rising, as are the treatment options for those men diagnosed with the disease. This cancer tops the list of new cancer cases for men in 2014, double that of new lung cancer cases; additionally nearly 30,000 men died from prostate cancer in 2014 in the US, making it the second most deadly after lung cancer, according to the American Cancer Society. The global treatment market for prostate cancer is expected to nearly double from $7.6 billion in 2014 to $13.6 billion by 2021, according to business intelligence provider GBI research, which attributes the rise to an aging global population.

In recognition of “Movember” – a men’s health awareness movement in November, the Evidence-Based Medicine Center at Elsevier Clinical Solutions decided to shed light on common questions and situations faced by both physicians and patients.

Dr. David Goldmann, head of the EBM Center, called upon Dr. Alan J. Wein, Chief of the Division of Urology at the Perelman School of Medicine, Hospital of the University of Pennsylvania, and Senior Editor of Campbell-Walsh Urology. For this series of video interviews, Dr. Wein is interviewed by Dr. Peter Edelstein, Chief Medical Officer of Elsevier Clinical Solutions.

Prostate Cancer Screening: The Who, What and Why?

Dr. Wein and Dr. Edelstein discuss various prostate cancer screening topics, including the PSA test, what physicians should ask patients, and the options patients need to consider when deciding with their physicians on treatments.

Prostate Cancer Screening: The Patient

Hear what patients should be asking their doctors when diagnosed prostate cancer as well as diagnoses, options, treatment and more.

Prostate Cancer Screening: The Evidence

As more primary care physicians see patients who could and should be screened for prostate cancer, increasingly they will hear basic questions over who should be screened and when screening should start. Dr. Wein talks about guidelines for prostate cancer screening: Physicians usually consult guidelines produced by medical societies or associations, like the American Medical Association, but many different medical organizations have come out with sometimes differing guidelines, according to Dr. Wein.

Selected research by Dr. Wein

Dr. Alan J. Wein was a co-author on these studies. Elsevier has made them freely available until March 17, 2016:

New textbook by Dr. Wein et al

Dr. Alan J. Wein is Senior Editor of the 11th edition of Campbell-Walsh Urology, which was just released. This updated four-volume set has 22 new chapters and features hundreds of respected global contributors at the top of their fields. It highlights the essential concepts necessary for every stage of a physician’s career, from anatomy and physiology through the latest diagnostic approaches and medical and surgical treatments. “The text continues to offer the most comprehensive coverage of every aspect of urology for urologists, residents and practicing physicians alike,” Dr. Wein said.

Elsevier Connect Contributor

Christopher Capot

As Director of Corporate Relations, Christopher Capot (@Chris_Capot) heads up public relations for Elsevier's Clinical Solutions and Education businesses. He has been a public relations and media relations professional at agencies and corporations for more than 15 years. Prior to that, he was an award-winning newspaper journalist, last working as a business reporter at the New Haven Register in Connecticut. He works in Elsevier's New York office.

comments powered by Disqus

Related Stories